Search

Global shortages of critical equipment and supplies induced by COVID-19 forced countries to rapidly build and ramp up their indigenous testing and production capacities. However, the many ways in which institutional and organizational change occurred has not been sufficiently captured. Building domestic capacity requires the leveraging and repurposing of existing domestic scientific and technological capabilities, coupled with intensified global outreach to new and existing partners and suppliers. Using the framework of institutional variety, this paper looks at two facets of the UK's COVID emergency industrial response: (1) building its laboratory testing capabilities and (2) for increasing production of personal protective equipment; assessing the institutional capacities and relations that were leveraged in this regard. It uses these findings together with observations of 'innovation processes under emergency conditions' and the potential uses of a 'critical equipment policy' to sharpen some of the recommendations made in the UK's post-COVID Research and Development Roadmap. [ABSTRACT FROM AUTHOR]

Investment in biotechnology has yielded relatively disappointing results and illustrates the gap between the promise and reality of new science. This begs the question: Does research on 'life' bring different complexities and uncertainties that act as a barrier to the application of new biology in global health and agriculture? There has been high-quality research on the social and ethical impacts of new biology and on the economics of biotechnology but few systematic and integrated attempts to undertake interdisciplinary research and address these constraints. This paper provides an original empirical analysis of contemporary and future understandings of the bioeconomy using a co-evolutionary and interactive approach to examine the extent to which it may be different from other technological transformations. We focus on the Innogen Centre's extensive research results on three important and contemporary themes: food and energy security, life science and healthcare translational medicine, and global health. [ABSTRACT FROM AUTHOR]

'Brain drain' is viewed as a curse for developing countries but analysis suggests it may provide crucial advantage to some countries. 'Reverse brain drain' of engineers and scientists trained in the USA or Europe can accelerate technological catch-up. Communities of returned scientists and engineers can provide skill and know-how to help local firms shift to higher value-added activities. However, transfer of knowledge through human mobility is not a straightforward process. This paper presents insights regarding diffusion of knowledge through migration of scientific labour, using case studies of innovative Indian pharmaceutical firms. [ABSTRACT FROM AUTHOR]

Despite various institutional reforms in the European Union (EU), regulatory procedures for genetically modified (GM) products are still held up by disagreements among experts; claims about a product's safety often correspond to a narrower account of precaution than broader counter-claims from objectors. In the EU, we argue, these conflicts have given practical meaning to the concept of precaution, rather than any explicit interpretation of an a priori principle. Through dynamic tensions between the various claims and accounts of precaution, EU regulatory-expert procedures have identified and addressed more scientific uncertainties than before. Yet decisions about GM products still face legitimacy problems, because they arise fundamentally from the great burden placed on science as the basis for societal choices about agri-biotechnology [ABSTRACT FROM AUTHOR]

Most policy-makers, academics and business people still perceive R&D as a single well-defined thing instead of a multi-facetted activity. Even after decades of debate and critique of simplistic notions of what is R&D, narrow conceptions of R&D are still prevalent and lead inexorably to inadequate appreciation of the strategic options for increasing or improving R&D activities. This is an issue for all firms but especially those in follower nations, those that have low human and financial resources available for R&D. This paper aims to build a picture of the range of R&D activities, using examples, in the main, from Indian and South Korean companies. A picture is built of high variety, where the key element is catch-up, making the R&D task quite different to that in leader firms and nations. The paper also begins consideration of the implications for company strategy and public policy, arguing that each must change if follower firms are to improve towards leadership through innovation. [ABSTRACT FROM AUTHOR]